Literature DB >> 4189764

Amantadine in Parkinson's disease.

P Millac, I Hasan, M L Espir, D G Slyfield.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 4189764     DOI： 10.1016/s0140-6736(70)90850-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

2.  On the effect of amantadine on monoamines and their metabolites in the brain and cerebrospinal fluid.

Authors:  U K Rinne; V Sonninen; M Hyyppä
Journal:  Experientia       Date:  1972-01-15

3.  Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study.

Authors:  A Barbeau; H Mars; M I Botez; M Joubert
Journal:  Can Med Assoc J       Date:  1971-07-10       Impact factor: 8.262

Review 4.  Speech disorders of Parkinsonism: a review.

Authors:  E M Critchley
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-09       Impact factor: 10.154
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.